JP2020507332A5 - - Google Patents

Download PDF

Info

Publication number
JP2020507332A5
JP2020507332A5 JP2019544614A JP2019544614A JP2020507332A5 JP 2020507332 A5 JP2020507332 A5 JP 2020507332A5 JP 2019544614 A JP2019544614 A JP 2019544614A JP 2019544614 A JP2019544614 A JP 2019544614A JP 2020507332 A5 JP2020507332 A5 JP 2020507332A5
Authority
JP
Japan
Prior art keywords
cancer
protein
pharmaceutical composition
composition according
salmonella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019544614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507332A (ja
JP7712060B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/053918 external-priority patent/WO2018149982A1/en
Publication of JP2020507332A publication Critical patent/JP2020507332A/ja
Publication of JP2020507332A5 publication Critical patent/JP2020507332A5/ja
Priority to JP2023133276A priority Critical patent/JP2023160838A/ja
Application granted granted Critical
Publication of JP7712060B2 publication Critical patent/JP7712060B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019544614A 2017-02-17 2018-02-16 新規vegfr-2ターゲット免疫療法アプローチ Active JP7712060B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023133276A JP2023160838A (ja) 2017-02-17 2023-08-18 新規vegfr-2ターゲット免疫療法アプローチ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17156718 2017-02-17
EP17156718.3 2017-02-17
PCT/EP2018/053918 WO2018149982A1 (en) 2017-02-17 2018-02-16 Novel vegfr-2 targeting immunotherapy approach

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023133276A Division JP2023160838A (ja) 2017-02-17 2023-08-18 新規vegfr-2ターゲット免疫療法アプローチ

Publications (3)

Publication Number Publication Date
JP2020507332A JP2020507332A (ja) 2020-03-12
JP2020507332A5 true JP2020507332A5 (enExample) 2021-03-25
JP7712060B2 JP7712060B2 (ja) 2025-07-23

Family

ID=58094260

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019544614A Active JP7712060B2 (ja) 2017-02-17 2018-02-16 新規vegfr-2ターゲット免疫療法アプローチ
JP2023133276A Withdrawn JP2023160838A (ja) 2017-02-17 2023-08-18 新規vegfr-2ターゲット免疫療法アプローチ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023133276A Withdrawn JP2023160838A (ja) 2017-02-17 2023-08-18 新規vegfr-2ターゲット免疫療法アプローチ

Country Status (13)

Country Link
US (1) US10980868B2 (enExample)
EP (1) EP3583200A1 (enExample)
JP (2) JP7712060B2 (enExample)
KR (2) KR20240170928A (enExample)
CN (1) CN110291187A (enExample)
AU (1) AU2018222777B9 (enExample)
BR (1) BR112019016925A2 (enExample)
CA (1) CA3050833A1 (enExample)
IL (1) IL268186A (enExample)
MX (1) MX2019009724A (enExample)
RU (1) RU2019125436A (enExample)
SG (1) SG11201907391SA (enExample)
WO (1) WO2018149982A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2760699T3 (es) * 2015-06-18 2020-05-14 Vaximm Ag Vacuna de ADN dirigida al VEGFR-2 para terapia de combinación
KR20210058825A (ko) * 2018-09-05 2021-05-24 백심 아게 병용 요법용 신생항원 표적화 dna 백신
KR20220128638A (ko) * 2020-01-13 2022-09-21 백심 아게 항생제와 조합되는 살모넬라-기반의 dna 백신
CN113527509B (zh) * 2020-04-17 2023-09-26 深圳华大生命科学研究院 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
JP6251179B2 (ja) * 2011-12-22 2017-12-20 バクシム アクチェンゲゼルシャフト 弱毒化サルモネラ株を高収量で生産する方法
WO2014005683A1 (en) * 2012-07-05 2014-01-09 Vaximm Ag Dna vaccine for use in pancreatic cancer patients
SI2988762T1 (sl) * 2013-04-25 2018-10-30 Vaximm Ag Vektorji na osnovi salmonele za imunoterapijo raka, usmerjeno v Wilmsov tumorski gen WT1
JP6662787B2 (ja) * 2013-12-18 2020-03-11 バキシム ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌免疫療法のための新規msln標的化dnaワクチン
WO2015142875A1 (en) * 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compositions and methods using modified salmonella
ES2760699T3 (es) 2015-06-18 2020-05-14 Vaximm Ag Vacuna de ADN dirigida al VEGFR-2 para terapia de combinación
CA3028549A1 (en) 2016-07-13 2018-01-18 Vaximm Ag Process for the production of a dna vaccine for cancer immunotherapy

Similar Documents

Publication Publication Date Title
JP2020511139A5 (enExample)
Chien et al. Advances in bacterial cancer therapies using synthetic biology
Fan et al. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity
RU2019132253A (ru) Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака
Piper et al. Glioma stem cells as immunotherapeutic targets: advancements and challenges
Weichselbaum The 46th David A. Karnofsky Memorial Award lecture: oligometastasis—from conception to treatment
JP6945301B2 (ja) Hpvおよび関連する疾病のための免疫増強治療ワクチン
RU2016129044A (ru) Новая вакцина днк, нацеленная на мезотелин, для иммунотерапии рака
RU2015103758A (ru) Днк-вакцина для применения у пациентов с раком поджелудочной железы
US10987432B2 (en) Therapeutic delivery and expression system, methods and uses thereof
Mei et al. Combining DNA vaccine and AIDA-1 in attenuated Salmonella activates tumor-specific CD4+ and CD8+ T-cell responses
Kang et al. Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects
JP2018517419A5 (enExample)
RU2018101722A (ru) Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
RU2019125436A (ru) Новый подход к иммунотерапии, нацеленной на vegfr-2
CN114592010A (zh) NK-CAR-MbIL-15细胞及其制备方法和应用
CN110408634B (zh) 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
US20230046425A1 (en) Immunotherapy for direct reprogramming of cancer cells into immune cells/antigen presenting cells/dendritic cells
EP2826856A1 (en) Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
RU2019112977A (ru) Днк-вакцина, нацеленная на wt1, для комбинированной терапии
Sampath et al. Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses
Kim et al. Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism
Ye et al. Oncolytic vaccinia virus expressing non-secreted decoy-resistant IL-18 mutein elicits potent antitumor effects with enhanced safety
Ahn et al. Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers
KR102706758B1 (ko) 암의 예방 및 치료용 살모넬라 균주 및 이의 용도